Pre-earnings brief
Reports
Mon, Nov 9, 2026
Est. EPS
—
Est. revenue
—
Implied move
±19.4%
EPS beat rate
50%
Belite Bio, Inc. operates in the health care sector, focusing on developing innovative pharmaceuticals. With a market cap of $6 billion, the company is involved in addressing significant health challenges, making it a key player in the pharmaceuticals industry.
Last quarter
In Q2 2026, Belite Bio reported an EPS of -$0.54, outperforming expectations by 26%. However, the stock fell by 7.07% the following day, indicating mixed investor sentiment.
EPS beat streak
3Q
EPS beat rate
50%
Avg EPS surprise
+4.11%
Avg 1-day reaction
-0.39%
Overall, Wall Street is cautious ahead of the upcoming earnings report, given the mixed performance in previous quarters.
Bull case
If Belite can continue to beat EPS estimates, it may indicate strong operational efficiency and investor confidence, potentially driving the stock higher.
Bear case
Conversely, if the company fails to meet expectations, it could raise concerns about its growth prospects and lead to further stock declines.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
EPS is a key measure of profitability, and any significant deviation from expectations could impact investor sentiment.
Q2
How is revenue trending compared to previous quarters?
Revenue growth is critical for assessing the company's market position and future prospects.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±23.2%
Why consensus could be wrong
The Street may be underestimating Belite's ability to improve its EPS this quarter, given its recent performance trends.
Supporting evidence
The company has shown a consistent ability to surprise on EPS in the past, with a 50% beat rate.
Options pricing suggests a significant move, indicating that investors are anticipating volatility.
Key risk
If the EPS comes in better than -$0.40, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it may indicate the company's ability to recover from previous earnings misses.
Bull confirmed if
An EPS of -$0.40 or better would confirm the bull case, indicating improved profitability.
Bear confirmed if
An EPS worse than -$0.70 would confirm the bear case, raising concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±19.41%
Historical Avg
±3.2%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±19.4% while BLTE has averaged ±3.2% over the last 8 prints — setup is pricing rich.
30d HV
53.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.2%, with a raw directional average of -0.2% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$82,658.89
500 sh
1 insider
Net
$82,658.89
Net selling
Most Active Insiders· 8 open-market trades
$82,658.89
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Belite beats expectations, history suggests the stock could see a modest increase, confirming operational strength.
In line / cautious
An in-line report may lead to a muted reaction, as investors weigh management's commentary for future guidance.
Miss
If the company misses expectations, history suggests a potential decline in stock price, reflecting investor disappointment.
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $163.63
200 sh
$32,725.00
Oct 1, 2026 · @ $165.49
120 sh
$19,859.22
Oct 1, 2026 · @ $167.59
78 sh
$13,071.83
Oct 1, 2026 · @ $166.44
50 sh
$8,321.84
Oct 1, 2026 · @ $164.64
24 sh
$3,951.38
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.